Welcome!

News Feed Item

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

LONDON, April 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/non_small_cell_lung_cancer_global_clinical_trials_review.html

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014" provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Small Cell Lung Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Small Cell Lung Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 6
Non-Small Cell Lung Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Non-Small Cell Lung Cancer 25
Subjects Recruited Over a Period of Time 57
Clinical Trials by Sponsor Type 58
Prominent Sponsors 59
Top Companies Participating in Non-Small Cell Lung Cancer Therapeutics Clinical Trials 60
Prominent Drugs 62

Latest Clinical Trials News on Non-Small Cell Lung Cancer 63
Mar 02, 2014: Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer 63
Feb 19, 2014: Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival 63
Feb 17, 2014: Afatinib: added benefit depends on mutation status 64
Jan 27, 2014: Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer 65
Jan 16, 2014: ArQule Provides Updates on Clinical Trials in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer with Tivantinib 66
Clinical Trial Profiles 68
Clinical Trial Overview of Top Companies 68
F. Hoffmann-La Roche Ltd. 68
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 68
Eli Lilly and Company 84
Clinical Trial Overview of Eli Lilly and Company 84
AstraZeneca PLC 98
Clinical Trial Overview of AstraZeneca PLC 98
Pfizer Inc. 109
Clinical Trial Overview of Pfizer Inc. 109
Bristol-Myers Squibb Company 117

Clinical Trial Overview of Bristol-Myers Squibb Company 117
Sanofi 123
Clinical Trial Overview of Sanofi 123
Novartis AG 128
Clinical Trial Overview of Novartis AG 128
Merck & Co., Inc. 133
Clinical Trial Overview of Merck & Co., Inc. 133
GlaxoSmithKline plc 137
Clinical Trial Overview of GlaxoSmithKline plc 137
C. H. Boehringer Sohn AG & Co. KG 141
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 141
Clinical Trial Overview of Top Institutes / Government 145
National Cancer Institute 145
Clinical Trial Overview of National Cancer Institute 145
The University of Texas M. D. Anderson Cancer Center 168
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 168
Memorial Sloan Kettering Cancer Center 172
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 172
West Japan Oncology Group 176
Clinical Trial Overview of West Japan Oncology Group 176
European Organization for Research and Treatment of Cancer 179
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 179
Radiation Therapy Oncology Group 182
Clinical Trial Overview of Radiation Therapy Oncology Group 182
Sun Yat-sen University 184
Clinical Trial Overview of Sun Yat-sen University 184

Eastern Cooperative Oncology Group 186
Clinical Trial Overview of Eastern Cooperative Oncology Group 186
Sarah Cannon Research Institute 188
Clinical Trial Overview of Sarah Cannon Research Institute 188
Barbara Ann Karmanos Cancer Institute 190
Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute 190
Five Key Clinical Profiles 192
Appendix 292
Abbreviations 292
Definitions 292
Research Methodology 293
Secondary Research 293
About GlobalData 294
Contact Us 294
Disclaimer 294
Source 295

List of Tables

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 21

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Non-Small Cell Lung Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Non-Small Cell Lung Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 28
Non-Small Cell Lung Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 33
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 57
Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 58
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 59
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 61
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 62
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 68
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 84
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 98

Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 109
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 117
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 123
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 128
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 133
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 137
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 141
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 145
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 168
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 172

Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by West Japan Oncology Group, 2014* 176
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 179
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Radiation Therapy Oncology Group, 2014* 182
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Yat-sen University, 2014* 184
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2014* 186
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sarah Cannon Research Institute, 2014* 188
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Barbara Ann Karmanos Cancer Institute, 2014* 190

List of Figures
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17

Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 57
Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 58
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 59
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 60
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 62
GlobalData Methodology 293

Read the full report:
Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/non_small_cell_lung_cancer_global_clinical_trials_review.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
While presenting own advanced Robo-Advisory Platform, Michał Różański, Managing Partner at EARP and CEO at Empirica, will illustrate the most important issues of building tailored FinTech software in his session at 20th Cloud Expo. He will share experiences we have gained for over 6 years of developing solutions for financial institutions and FinTech companies, including robo-advisors. We welcome all FinTech innovators interested in how properly implemented technology can move their businesses f...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo Silicon Valley Call for Papers is now open.
The 21st International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
As cloud adoption continues to transform business, today's global enterprises are challenged with managing a growing amount of information living outside of the data center. The rapid adoption of IoT and increasingly mobile workforce are exacerbating the problem. Ensuring secure data sharing and efficient backup poses capacity and bandwidth considerations as well as policy and regulatory compliance issues.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
SYS-CON Events announced today that Outscale will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outscale's technology makes an automated and adaptable Cloud available to businesses, supporting them in the most complex IT projects while controlling their operational aspects. You boost your IT infrastructure's reactivity, with request responses that only take a few seconds.
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing bes...
SYS-CON Events announced today that DivvyCloud will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. DivvyCloud software enables organizations to achieve their cloud computing goals by simplifying and automating security, compliance and cost optimization of public and private cloud infrastructure. Using DivvyCloud, customers can leverage programmatic Bots to identify and remediate common cloud problems in rea...
SYS-CON Events announced today that Tintri, Inc, a leading provider of enterprise cloud infrastructure, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Tintri offers an enterprise cloud platform built with public cloud-like web services and RESTful APIs. Organizations use Tintri all-flash storage with scale-out and automation as a foundation for their own clouds – to build agile development environments...
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs ofte...